Buy Aduhelm (aducanumab-avwa)

What is Aduhelm (aducanumab-avwa) for?

Aduhelm (aducanumab-avwa) is an amyloid beta-directed antibody used to treat people with mild cognitive impairment or mild dementia.^[1]

It is the first novel therapy approved for Alzheimer’s disease since 2003, and the first disease-modifying therapy for Alzheimer’s, targeting the underlying cause of Alzheimer’s disease, the presence of amyloid beta plaques in the brain.^[1]

It is available in vial form for intravenous infusion, containing either 170 mg/1.7 mL (100 mg/mL) and 300 mg/3 mL (100 mg/mL) aducanumab-avwa.^[1]

How does Aduhelm (aducanumab-avwa) work?

The active ingredient in Aduhelm, aducanumab-avwa, is a human-made antibody that is designed to remove toxic clumps (plaques) of the protein beta-amyloid. These plaques are thought to drive the death of nerve cells (neurons) in the brains of people with Alzheimer’s disease and cause symptoms of the disease.^[2]

Aduhelm is thought to bind to and reduce the amount of plaques in the brain of people with Alzheimer’s, thereby slowing down the progression of the disease.^[2]

Where has Aduhelm (aducanumab-avwa) been approved?

Aduhelm (aducanumab-avwa) was approved for the treatment of people with Alzheimer’s Disease by:

• The Food and Drug Administration (FDA), USA on June 7, 2021.^[3]

Aduhelm (aducanumab-avwa) was approved under Accelerated approval, based on the reduction of amyloid beta plaque size.^[3]

Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.

How is Aduhelm (aducanumab-avwa) taken?

The standard dosage is:^[1]

• Built up stepwise (titrated) up to 10 mg/kg body weight at the start of treatment
• Followed by a 10 mg/kg maintenance dose

Aduhelm (aducanumab-avwa) is administered through an IV line (intravenous) over approximately one hour every four weeks and at least 21 days apart.^[1]

Magnetic resonance imaging (MRI) scans will be done before and during treatment to check for Amyloid Related Imaging Abnormalities (ARIA).^[1]

Complete information about Aduhelm (aducanumab-avwa) dosage and administration can be found in the official prescribing information listed in our references section.^[1]

Note: Please consult with your treating doctor for personalised dosing.

Are there any known adverse reactions or side effects of Aduhelm (aducanumab-avwa)?

Common adverse reactions

The most common side effects ( ≥10% of patients and higher incidence compared to placebo) listed in the prescribing information include:^[1]

• Fluid accumulation in the brain (Amyloid Related Imaging Abnormalities (ARIA) edema)
• Headache
• ARIA-H microhemorrhage
• ARIA-H superficial siderosis
• Fall

Serious adverse reactions

The serious adverse reactions listed in the prescribing information include:^[1]

• Amyloid Related Imaging Abnormalities (ARIA)
• Hypersensitivity reactions

Use in a specific population

It is not yet known if Aduhelm (aducanumab-avwa) is fatal for a fetus, it is advised to avoid pregnancies. It is not known if Aduhelm (aducanumab-avwa) passes into your breast milk. Discuss with your treating doctor if you are pregnant or plan to become pregnant or are breastfeeding or plan to breastfeed.^[1]

For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information.^[1]

References

1. Full prescribing information [FDA]: Aduhelm (aducanumab-avwa) [PDF]
Biogen, Jun 2021

2. Aducanumab
Alzheimersnewstoday.com, cited Jun 2021

3. FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease
Biogen, Jun 2021